← Who reports today · Health Care
VTRS · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Revenue grew 4.9% y/y to $3.76B, operating margin 0.2% vs 6.5%, net loss $119M (vs net loss $4.6M a year earlier).
- Total revenues +4.9% — mainly new product sales in Developed Markets and growth in Greater China
Source
«Total revenues were $3.8 billion, up 5% on a reported basis and up 3.5% on an operational basis compared to second-quarter 2025 results, primarily driven by new product sales in Developed Markets and strong growth in Greater China.»
press release, 8-K
All figures in $M.
| Line item | Amount and change |
|---|---|
| Net sales | $3,746 · +5.0% |
| Other revenues | $10.9 · −16.8% |
| Total revenues | $3,757 · +4.9% |
| Acquired IPR&D | $5.8 · vs $0 |
| Other (income) expense, net | $50.4 · vs −$334 |
| Net (loss) earnings | $119 · ×26 |
| Cost of sales | $2,300 · +2.3% |
| Research and development | $248 · +13.5% |
| Selling, general and administrative | $1,135 · +22.2% |
| Litigation settlements and other contingencies, net | $73.2 · +53.8% |
| Interest expense | $121 · +3.5% |
| Income tax provision (benefit) | $54.8 |
Verdict: revenue grew 4.9% y/y to $3.76B, operating margin 0.2% vs 6.5%, net loss $119M (vs net loss $4.6M a year earlier).
U.S. GAAP gross margin 38.8% vs 37.2%; approximately $550 million returned to shareholders; gross leverage ratio reduced to 2.9x; 2026 guidance midpoints raised.
Source and notation
Source: Viatris press release, 8-K EX-99.1 of 08/06/2026 (SEC EDGAR). Every figure was matched against the income statement in the release and checked against SEC XBRL.
Open as an image: VTRS, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “VTRS Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/vtrs/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/vtrs/q2-2026"><img src="https://whoreportstoday.com/t/vtrs/q2-2026/sankey.png" alt="VTRS Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/vtrs/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/vtrs/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/vtrs/q2-2026">VTRS Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Total revenues rose 5% to $3,756.8M: Greater China grew 21% to $713.8M and Developed Markets 4%, while Emerging Markets (-2%) and JANZ (-3%) declined.
- Gross margin was 38.8% vs 37.2% a year earlier.
- Operating income was $6.3M, a 0.2% margin vs 6.5% a year earlier.
- Diluted EPS was −$0.10 vs $0.05 a year earlier.
What distorts the picture in this report and what to watch beyond the headlines.
VTRS — Viatris is a global healthcare company that sells branded and generic medicines, including off-patent brands, across developed and emerging markets.
Headquarters: Canonsburg, Pennsylvania.
Heads-up
- a net loss in Q2 2026 ($119 · ×26)
Net loss for Q2 2026: $119M. In the report's figures: costs grew faster than revenue: selling, general and administrative +22% y/y, litigation settlements and other contingencies, net +54% y/y, research and development +14% y/y. Based on the Q2 2026 report.
The company's report ↗More reports: WAT · Q3 2026 · WST · Q3 2026 · ZBH · Q3 2026 · ZTS · Q3 2026 · A · Q3 FY2026 · ABBV · Q3 2026 · ABT · Q3 2026 · ALGN · Q3 2026 · AMGN · Q3 2026 · BAX · Q3 2026 · all reports